Phenytoin immunoassay measurements in serum samples from patients with renal insufficiency: Comparison with high-performance liquid chromatography

Journal of Clinical Laboratory Analysis

Volumn 21, Issue 2, 2007, Pages 119-123

  Tutor Crespo, Maria J ^a   Hermida, Jesús ^a   Tutor, J Carlos ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Phenytoin immunoassays accuracy; Phenytoin metabolites; Renal insufficiency

Indexed keywords

PHENYTOIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; KIDNEY FAILURE; KIDNEY FUNCTION; MALE;

ADULT; AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PHENYTOIN; RENAL INSUFFICIENCY, ACUTE; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS;

EID: 34047230486     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20115     Document Type: Article

References (26)

1. Finn AL, Olanow CW. Phenytoin. Therapeutic use and serum concentration monitoring. In: Taylof WJ, Finn AL, editors. Individualizing drug monitoring. Practical applications of drug monitoring. Vol. 2. New York: Gross, Towsend, Frank, Inc.; 1981. p 63-85.
2. Maguire JH. Quantitative estimation of cathechol/methylcathechol pathways in human phenytoin metabolism. Epilepsia 1988;29:753-759.
3. Nakajima M, Sakata N, Ohashi N, Kume T, Yokoi T. Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4′-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. Drug Metab Dispos 2002; 27:1165-1170.
4. Yamanaka H, Nakajima M, Hara Y, et al. Urinary excretion of phenytoin metabolites, 5-(4′-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases. Drug Metab Pharmacokinet 2005;20:135-143.
5. Borga O, Hoppel C, Odar-Cederlof I, Garle M. Plasma levels and renal excretion of phenytoin and its metabolites in patients with renal failure. Clin Pharmacol Ther 1979;26:306-314.
6. Hoppel C, Garle M, Rane A, Sjöqvist F. Plasma concentration of 5-(4′-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients. Clin Pharmacol Ther 1977;21:294-300.
7. Burgess ED, Friel PN, Blair Jr AD, Raisys VA. Serum phenytoin concentrations in uremia. Ann Intern Med 1981;94:59-60.
8. Eadie MJ, Tyrer JH, Bochner F, Hooper WD. The elimination of phenytoin in man. Clin Exp Pharmacol Physiol 1976;3:217-224.
9. Flachs H, Rasmussen JM. Renal disease may increase apparent phenytoin in serum as measured by enzyme-multiplied immunoassay. Clin Chem 1980;26:361.
10. Rubenstein K, Bastiani R. Renal disease may increase apparent phenytoin in serum as measured by enzyme-multiplied immunoassay [reply]. Clin Chem 1980;26:362.
11. Sawchuk RJ, Matzque GR. Contribution of 5-(4-hydroxyphenyl)-5- phenylhydantoin to the discrepancy between phenytoin analyses by EMIT and high-pressure liquid chromatography. Ther Drug Monit 1984;6:97-103.
12. Roberts WL, Rainey PM. Interference in immunoassay measurements of total and free phenytoin in uremic patients: a reappraisal. Clin Chem 1993;39:1872-1877.
13. Rainey PM, Rogers KE, Roberts WL. Metabolite and matrix interference in phenytoin immunoassays. Clin Chem 1996; 42:1645-1653.
14. Datta P. Oxaprozin and 5-(p-hydroxyphenyl)-5-phenylhydantoin interference in phenytoin immunoassays. Clin Chem 1997; 43:1468-1469.
15. Frank EL, Schwartz EL, Juenke J, Annesley TM, Roberts WL. Performance characteristics of four immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer. Am J Clin Pathol 2002;118:124-131.
16. Datta P, Scurlock D, Dasgupta A. Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650® analyzer: effect of phenytoin metabolite and analogue. Ther Drug Monit 2005;27:305-308.
17. Soldin SJ, Wang E, Verjee Z, Elin RJ. Phenytoin overview-metabolite interference in some immunoassays could be clinically important. Arch Pathol Lab Med 2003;127:1623-1625.
18. Roberts WL, Rainey PM. Phenytoin overview-metabolite interference in some immunoassays could be clinically important. Arch Pathol Lab Med 2004;128:734.
19. Soldin SJ, Guo T, Wang E, Verjee Z, Elin RJ. Phenytoin overview-metabolite interference in some immunoassays could be clinically important. Arch Pathol Lab Med 2004;128:734-735.
20. Larsson A, Malm J, Grubb A, Hansson LO. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004;64:25-30.
21. Eksborg S. Evaluation of method-comparison data. Clin Chem 1981;27:1311-1312.
22. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability. bioequivalence and pharmacokinetics studies. Eur J Drug Metab Pharmacokinet 1991;16:249-255.
23. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-226.
24. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate. Clin Chem 2002;48:699-707.
25. Perucca E, Richens A. Antipileptic drugs: clinical aspects. In: Richens A, Marks V, editors. Therapeutic drug monitoring. Edinburgh: Churchill Livingstone; 1981. p 320-348.
26. Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. Clin Chem 1998;44:1085-1095.